Avidity Biosciences Inc

RNA

Equity

ISIN US05370A1088 / Valor 54991635

NASDAQ (2024-11-20)

USD 43.65+0.92%

Avidity Biosciences Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Avidity Biosciences Inc. is a biotechnology company focused on developing a new class of RNA therapeutics known as Antibody Oligonucleotide Conjugates (AOCs). These AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, targeting the root causes of diseases that were previously untreatable with RNA-based treatments. The company has three primary clinical development programs targeting rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral muscular dystrophy (FSHD). Their lead product candidate, delpacibart etedesiran (AOC 1001), is advancing to Phase 3 trials for DM1. Additionally, AOC 1020 and AOC 1044 are in Phase 1/2 trials for FSHD and DMD, respectively. Avidity is also expanding its pipeline to include programs in precision cardiology and immunology, leveraging both internal research and strategic partnerships to extend the application of its AOC platform beyond muscle tissues.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

631%1Y

55.8%3Y

%5Y

Performance

77.3%1Y

78.4%3Y

76.5%5Y

Volatility